Back Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Sunday, July 26, 2015 Read the Story Here Share Related Posts Discover more posts like this. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma Mar 6, 2024 Douglass Orr, MD A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors Mar 6, 2024 Minal Barve, MD PHASE 1 FIRST-IN- HUMAN STUDY OF DALUTRAFUSP ALFA, Cluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and can lead to protumor conditions.... Jul 26, 2023 See All Posts